Japan · Delayed Price · Currency is JPY Mitsui Chemicals Earnings Call Transcripts
Fiscal Year 2026
-
Operating income before special items fell 10% year-on-year for April–December 2025, with net income down due to restructuring costs. Full-year guidance was revised downward, but Specialty Chemicals remains strong, and a JPY 30.0 billion share repurchase is planned.
-
Specialty chemicals delivered solid results, offsetting weakness in basic and green materials, with H1 FY2025 operating income before special items at JPY 44.5 billion and a full-year forecast of JPY 110.0 billion. Net income was impacted by restructuring, but cash flow remains strong.
-
First quarter FY2025 saw lower sales and profits year-on-year, mainly due to restructuring costs and weaker basic and green materials, while specialty chemicals and ICT solutions showed resilience. The outlook for the first half remains cautious, with continued monitoring of external risks and a stable dividend forecast.
Fiscal Year 2025
-
Operating income before special items grew 5% in fiscal year 2024, driven by specialty chemicals and restructuring, while net income declined due to impairments and tax expenses. Fiscal year 2025 projects further profit growth, with risks from U.S. trade policies and yen appreciation.
-
Operating income before special items rose 5% year-over-year for April–December 2024, with strong Specialty Chemicals offsetting Basic & Green Materials weakness from an ethylene plant failure. Full-year guidance remains unchanged, with higher dividends and treasury stock buybacks.
-
Operating income before special items rose 26% year-over-year in H1 FY2024, with net income and sales revenue also increasing. Despite a downward revision due to the Osaka plant failure, full-year operating income is still forecast to grow 9% year-over-year.
-
Q1 FY2024 saw strong year-on-year growth in revenue and profits, driven by sales recovery, yen depreciation, and improved terms of trade. Outlook for H1 FY2024 remains positive, though risks from an ethylene plant failure and market recovery delays persist.